Pfizer Cash Conversion Cycle from 2010 to 2026
| PFE Stock | EUR 23.44 0.07 0.30% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter 198.04 | Current Value 217.55 | Quarterly Volatility 48.91750134 |
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Discontinued Operations of 6.6 M, Interest Expense of 3.7 B or Selling General Administrative of 11.2 B, as well as many indicators such as Price To Sales Ratio of 2.16, Dividend Yield of 0.0727 or PTB Ratio of 1.85. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
Pfizer | Cash Conversion Cycle |
The Cash Conversion Cycle trend for Pfizer Inc offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Pfizer is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Pfizer's Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of Pfizer Inc over the last few years. It is Pfizer's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
Pfizer Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | 168.73 | |
| Geometric Mean | 161.67 | |
| Coefficient Of Variation | 28.99 | |
| Mean Deviation | 37.85 | |
| Median | 172.21 | |
| Standard Deviation | 48.92 | |
| Sample Variance | 2,393 | |
| Range | 207 | |
| R-Value | (0.26) | |
| Mean Square Error | 2,384 | |
| R-Squared | 0.07 | |
| Significance | 0.32 | |
| Slope | (2.49) | |
| Total Sum of Squares | 38,287 |
Pfizer Cash Conversion Cycle History
About Pfizer Financial Statements
Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | 198.04 | 217.55 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Pfizer Correlation against competitors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.